ReviewJournal of ophthalmology2026
Diabetic Retinopathy Detection: AI Models and Approaches.
Review in Journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diabetic Retinopathy Detection: AI Models and Approaches.Journal of ophthalmology · 2026Review
- Why aren't we using AI in eye clinics? A systematic review of barriers and solutions in AI-based fundus image diagnostics for ocular diseases.International journal of ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic retinopathy (DR), a major cause of vision loss worldwide, results from chronic diabetes damage to retinal blood vessels. Vision loss can be prevented if DR is detected early, but traditional retinal screening by eye care takes time and expertise. Recent advances in AI technology, including classical machine learning and deep learning, can be more accurate in DR detection. This article provides a comprehensive review of current AI models and approaches of DR screening. Methods: We searched PubMed, Web of Science, Scopus, ScienceDirect, and EBSCOhost using the keywords: diabetes, retinopathy, screening, and early detection. The search was limited to English language and studies published between 2020 and 2025. Results: The findings suggest that AI models have become crucial for early DR diagnosis. While traditional machine learning previously lacked effectiveness, deep learning has now significantly improved diagnostic performance. The models, such as the URNet system, the vision transformer (ViT) model, the ResNet-50 and EfficientNetB0 models, the DenseNet model, and the ResNet-18 model, have achieved high-performance metrics using publicly available datasets. DR screening devices, like ADX-DR, have shown commendable performance. The EyeArt modality demonstrated exceptional sensitivity across diverse populations, detecting around 98.5% of vision-threatening DR, while Google AI matched specialist performance in specificity and surpassed it in sensitivity. Conclusion: AI methods using deep learning frameworks such as CNNs have attained expert-level accuracy in DR classification, in addition to real-world validation. Semiautonomous systems like the IDx-DR and EyeArt have robust clinical performance and scalability, especially in countries with few ophthalmologists. Although research has been mainly conducted in Asia, there is a lack of research from Africa and low-income countries. Future techniques, including ensemble models and federated learning, will enhance accuracy and reliability further, aiding early diagnosis and prevention of vision loss globally.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.